Literature DB >> 8461649

Effect of using safer blood products on prevalence of HIV infection in haemophilic Canadians. Canadian Hemophilia Clinic Directors Group.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8461649      PMCID： PMC1676860          DOI： 10.1136/bmj.306.6873.306

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

Review 1.  HIV-1 infection in haemophilia.

Authors:  R Madhok; C D Forbes
Journal:  Baillieres Clin Haematol       Date:  1990-01

Review 2.  The development of virus-free labile blood derivatives--a review.

Authors:  A M Prince; B Horowitz; M S Horowitz; E Zang
Journal:  Eur J Epidemiol       Date:  1987-06       Impact factor: 8.082
  2 in total
  2 in total

Review 1.  Blood safety and the choice of anti-hemophilic factor concentrate.

Authors:  Leonard A Valentino; Veeral M Oza
Journal:  Pediatr Blood Cancer       Date:  2006-09       Impact factor: 3.167

2.  First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System.

Authors:  A N Traore; A K C Chan; K E Webert; N Heddle; B Ritchie; J St-Louis; J Teitel; D Lillicrap; A Iorio; I Walker
Journal:  Haemophilia       Date:  2014-07       Impact factor: 4.287
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.